1. Home
  2. SPE vs KRRO Comparison

SPE vs KRRO Comparison

Compare SPE & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Special Opportunities Fund Inc

SPE

Special Opportunities Fund Inc

HOLD

Current Price

$13.87

Market Cap

154.0M

Sector

Finance

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$10.90

Market Cap

150.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPE
KRRO
Founded
1993
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
154.0M
150.0M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SPE
KRRO
Price
$13.87
$10.90
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
31.3K
82.7K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
8.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$13.43
$5.20
52 Week High
$15.99
$55.89

Technical Indicators

Market Signals
Indicator
SPE
KRRO
Relative Strength Index (RSI) 39.01 44.15
Support Level $13.95 $10.35
Resistance Level $14.12 $14.52
Average True Range (ATR) 0.18 0.91
MACD -0.07 -0.24
Stochastic Oscillator 19.30 38.82

Price Performance

Historical Comparison
SPE
KRRO

About SPE Special Opportunities Fund Inc

Special Opportunities Fund Inc is a closed-ended diversified management investment company. Its investment objective is to have the total return. The company's investment portfolio consists of investment companies, common stocks, money market funds, commodity partnerships, preferred stocks, convertible bonds, liquidating trusts, promissory notes, senior unsecured notes, warrants, rights, corporate notes and corporate bonds.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: